ArticleCadernos de saude publica2025
Survival time analysis in women with breast cancer using distributional regression models.
Article in Cadernos de saude publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a global public health concern due to its high mortality rates. In Brazil, breast cancer is one of the leading causes of disease and death among women in all regions of the country, with higher mortality rates in less developed regions. Hence, this study analyzes variables associated with survival time in breast cancer patients in Campina Grande, Paraíba State, Brazil. Distributional regression models, also known as generalized additive models for location, scale, and shape (GAMLSS), were used due to their flexibility in explaining complex behaviors of a given response (for example, survival time) based on other variables. Tumor site, age, number of hormone therapy, radiotherapy and chemotherapy sessions, and molecular markers such as estrogen receptor, progesterone receptor, Ki-67 protein, p53, HER2 mutation and molecular subtype were examined. Two different GAMLSS were fitted considering Weibull and log-normal distributions, the former of which is more appropriate per the Akaike information criterion. Using a variable selection procedure specific to GAMLSS, we identified four covariates that directly affect average survival time: number of hormone therapy and chemotherapy sessions, p53 status, and estrogen receptor status. Excepting estrogen receptor status, the other covariates selected to explain average survival time were also used to explicitly explain the variability of these times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.